de Geus, Anna http://orcid.org/0000-0002-2282-0128
Koppen, Ilan J. N.
Flint, Robert B.
Benninga, Marc A.
Tabbers, Merit M.
Article History
Accepted: 19 February 2023
First Online: 20 March 2023
Declarations
:
: No sources of funding were used to support the writing of this article.
: Anna de Geus, Robert B. Flint, and Merit M. Tabbers have no conflicts of interest that are directly relevant to the content of this article. Ilan J.N. Koppen has received consulting fees from Mahana Therapeutics, a speaker fee from Wellspect, and funding for an investigator-initiated study from Wellspect. All of the above were related to the topic of functional gastrointestinal disorders, but not related to any pharmacological treatment. Marc A. Benninga is consultant for Mallinckrodt, Shire, Danone, FrieslandCampina, HIPP, Norgine, Coloplast, United Pharmaceuticals, and Wellspect. All honoraria were paid to the hospital (Amsterdam UMC).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MMT received an invitation from the journal to write this article. The literature search and first draft of the manuscript was performed by AdG. All authors have made substantial contributions to the entire manuscript by providing critical revisions on the work that have led to the manuscript. All authors have read and approved the final version of the manuscript.